Sarepta (SRPT) Exon45/53 Ph3 Trial Extension Has Negative Readthrough to Eteplirsen - Jefferies
Tweet Send to a Friend
Jefferies analyst Gena Wang reiterated an Underperform rating and $7 price target on Sarepta Therapeutic (NASDAQ: SRPT) noting the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE